Provided by Tiger Fintech (Singapore) Pte. Ltd.

Day One Biopharmaceuticals Inc.

7.22
-0.4900-6.36%
Post-market: 7.390.1700+2.35%16:53 EDT
Volume:934.43K
Turnover:6.75M
Market Cap:731.78M
PE:-7.05
High:7.70
Open:7.55
Low:7.06
Close:7.71
Loading ...

Company Profile

Company Name:
Day One Biopharmaceuticals Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
181
Office Location:
1800 Sierra Point Parkway,Suite 200,Brisbane,California,United States
Zip Code:
94005
Fax:
- -
Introduction:
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Directors

Name
Position
Jeremy Bender
Chief Executive Officer, President and Director
Julie Grant
Chair of the Board, Director and Co-Founder
Natalie Holles
Lead Independent Director
Dan Becker
Director
John Josey
Director
Michael Gladstone
Director
Saira Ramasastry
Director

Shareholders

Name
Position
Jeremy Bender
Chief Executive Officer, President and Director
Charles York II
Chief Operating Officer, Chief Financial Officer and Secretary
Julie Grant
Chair of the Board, Director and Co-Founder
Samuel Blackman
Chief Medical Officer and Co-Founder